Did Eli Lilly Just One-Up Novo Nordisk?
The pharmaceutical industry is scrambling for breakthroughs in weight loss treatment. Demand for medications such as Ozempic, Wegovy, Mounjaro, and Zepbound is rising. All of these diabetes and obesity treatments are developed by just two companies: Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY). The two pharma giants are competing intensely.
While Novo Nordisk currently holds a commanding lead in the glucagon-like peptide 1 (GLP-1) market, Lilly may have just outmaneuvered its rival. Let's dig into a unique partnership that Lilly just struck and assess how it could help the company catch up to Novo Nordisk.
Earlier this year, Lilly released a direct-to-consumer online pharmacy called LillyDirect. The platform aims to facilitate patient care by helping people find doctors or have treatments delivered directly to their doors.
Source Fool.com
